🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to the Srinivas Viswanathan team! This has been a great collaboration, and I'm super happy to see it out. Featuring two sets of metabolomics data from our core where we confirmed faster turnaround of TCA metabolites in tRCC. nature.com/articles/s4225…

Excited to share our latest work on 5yr outcomes and prognostic value of residual cancer burden with neoadjuvant ADT+ARPI for high-risk prostate cancer, published in European Urology: sciencedirect.com/science/articl… Dana-Farber News Dana-Farber Lank Center for Genitourinary Oncology Adam Kibel Rana McKay, MD, FASCO David Einstein

In story 2, we uncover how neomorphic cancer mutations in KBTBD4, a recurrently mutated E3 ligase substrate receptor in medulloblastoma, precisely mimic UM171. This reveals how chemical & genetic neomorphs can act by the same principles & mechanism. 3/6 nature.com/articles/s4158…

Stay tuned 📻 for a tweetorial by our rising 🌟Mohammad Jad Moussa, MD, MSc covering our new paper in #kidneycancer

Check out our latest work on MDM2 as a validated target in #gbm. Super collaboration with Veronica Rendo Kalem Lee Sandro Santagata Rameen Beroukhim Patrick Wen and team Kartos Therapeutics and the patients who contributed science.org/doi/10.1126/sc…

1/5 Sharing our Clinical Cancer Research work establishing serum CA-125 as a biomarker for #RenalMedullaryCarcinoma. This is now the first cancer-associated blood biomarker to become standard of care and used globally for a #kidneycancer : aacrjournals.org/clincancerres/… The V Foundation for Cancer Research Chris Johnson Foundation Inc.

We report a new role for HIF in the regulation of endogenous retroviruses! It was a big collaborative effort to explore the HIF-mediated transcription, expression, and HLA presentation of ERVs in kidney cancer and leveraging them for immunotherapy cell.com/cell/fulltext/…

We are thrilled to share our March 2025 Postdoc Spotlight, featuring Prathyusha Konda, Ph.D. (Prathyusha Konda ✨) from the Viswanathan Lab (Srinivas Viswanathan)!

📣 Excited to announce the launch of a new patient-partnered research project today – @CountMeIn’s Translocation Renal Cell Carcinoma Project! Delighted to co-PI this project alongside Dr. Elizabeth Mullen ➡️ tRCCproject.org. Dana-Farber Boston Children's Broad Institute

Great time yesterday at the Penn Center for Genome Integrity PCGI Mini Symposium. Thanks for the opportunity to participate!

CMI launched a research initiative for patients with translocation renal cell carcinoma (#tRCC). Physicians treating individuals with tRCC can help by sharing this opportunity with patients. Learn more at trccproject.org and request materials here: bit.ly/tRCCRequest

📣 Online now! Our study shows how recurrent focal deletions constitute a mechanism by which cancer cells can dampen toxicity due to gene amplification. cell.com/cell-genomics/…

Our latest study in EMBO Mol. Medicine reveals how TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma (tRCC). We define tRCC as a novel metabolic subtype of renal cancer. IGBMC - Srinivas Viswanathan 🔗embopress.org/doi/full/10.10…

More impact, together! Count Me In is proud to join Broad Clinical Labs to expand access to research and center patients in biomedical discovery. Read more at the link below.

We report that Cyclin D1 is an important direct target of HIF2 that drives the proliferation of ccRCC. Our findings further support the notion of combining HIF2 and CDK4/6 inhibitors to enhance antitumor activities. Congrats to Nitin Shirole and the team!

We worked together with Sadeem Ahmad, Sun Hur, and others to understand how the PACT protein prevents the activation of the double-stranded RNA sensor PKR by endogenous cellular RNAs. nature.com/articles/s4146…

A new study from Damon Runyon Innovator Srinivas Viswanathan takes a closer look at the behavior of the “inactive” X chromosome—and offers a potential explanation for sex-based differences in cancer. Read more: bit.ly/4d2iQRd

1/5 People living with sickle-cell disease (SCD) face ↑ cancer risk, including #RenalMedullaryCarcinoma. Our latest Immunity study suggests a culprit is the reshaping CD8⁺ T cell chromatin by SCD 👉authors.elsevier.com/sd/article/S10… #MsaouelLab

📢 #ASCO25: AREN1721 trial in translocation RCC (tRCC) closed early due to poor accrual (n=13), but key signals emerged: 🧪 Nivolumab+axitinib➡️ PR in 33%, median PFS ↑ from 1.8 → 10.5 mo (p=0.0004) 💊 Nivo alone showed no activity ⚠️ No unexpected toxicities 🚨 Trial

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4521: Dr #JAmesGeller presenting Nivo/Axitinib vs Nivo in pts with translocation RCC #AREN1721 🩺Clinical implications: - Nivo/Axitinib (n=6) showed early efficacy ORR 33% and mPFS 10mo - #TranslocationRCC remains a disease of unmet